Float Short %

20.55

Margin Of Safety %

-8

Put/Call OI Ratio

0.45

EPS Next Q Diff

-1.16

EPS Last/This Y

1.88

EPS This/Next Y

-1.58

Price

22.29

Target Price

33.95

Analyst Recom

1.91

Performance Q

12.92

Upside

-82.5%

Beta

0.24

Ticker: APLS

20 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-01-23	APLS	21.76	0.43	0.09	21435
2026-01-26	APLS	21.99	0.44	0.30	21329
2026-01-27	APLS	21.82	0.43	5.00	21512
2026-01-28	APLS	23.11	0.44	0.04	21530
2026-01-29	APLS	23.05	0.43	0.03	21648
2026-01-30	APLS	22.41	0.43	7.02	21686
2026-02-02	APLS	22.82	0.46	0.01	22038
2026-02-03	APLS	23.33	0.46	0.08	22133
2026-02-04	APLS	23.17	0.46	1.11	21923
2026-02-05	APLS	22.64	0.46	0.40	21887
2026-02-06	APLS	23.45	0.46	1.18	21913
2026-02-09	APLS	22.84	0.45	2.73	21952
2026-02-10	APLS	22.58	0.45	0.04	21862
2026-02-11	APLS	22.3	0.45	999.99	21865
2026-02-12	APLS	22.13	0.45	0.13	21980
2026-02-13	APLS	21.69	0.45	1.39	21998
2026-02-17	APLS	21.56	0.45	0.05	21997
2026-02-18	APLS	22.18	0.45	1.28	21905
2026-02-19	APLS	22.72	0.46	0.05	22042
2026-02-20	APLS	22.28	0.45	0.11	22036
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

20 items 1 of 1

20 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-01-23	APLS	21.75	-41.1	-225.0	0.28
2026-01-26	APLS	21.98	-38.2	-228.1	0.28
2026-01-27	APLS	21.82	-34.5	-225.6	0.28
2026-01-28	APLS	23.09	-34.5	-234.6	0.28
2026-01-29	APLS	23.03	-34.5	-226.4	0.28
2026-01-30	APLS	22.57	-34.5	-223.8	0.28
2026-02-02	APLS	22.83	-34.5	-228.1	0.28
2026-02-03	APLS	23.32	-34.5	-229.6	0.28
2026-02-04	APLS	23.17	-34.5	-	0.28
2026-02-05	APLS	22.56	-36.4	-	0.28
2026-02-06	APLS	23.47	-36.4	-	0.28
2026-02-09	APLS	22.83	-36.4	-	0.28
2026-02-10	APLS	22.58	-36.4	-	0.28
2026-02-11	APLS	22.30	-36.4	-	0.28
2026-02-12	APLS	22.03	-36.4	-	0.28
2026-02-13	APLS	21.70	-36.4	-	0.28
2026-02-17	APLS	21.56	-36.4	-	0.28
2026-02-18	APLS	22.19	-36.4	-	0.28
2026-02-19	APLS	22.80	-36.4	-	0.28
2026-02-20	APLS	22.29	-36.4	-	0.28
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

20 items 1 of 1

20 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-01-23	APLS	-2.31	-1.38	15.51
2026-01-26	APLS	-2.31	-1.39	15.51
2026-01-27	APLS	-2.31	-1.39	15.51
2026-01-28	APLS	-2.31	-1.39	17.42
2026-01-29	APLS	-2.31	-1.39	17.41
2026-01-30	APLS	-2.32	-1.39	17.41
2026-02-02	APLS	-2.32	-1.45	17.41
2026-02-03	APLS	-2.32	-1.45	17.41
2026-02-04	APLS	-2.32	-1.45	17.41
2026-02-05	APLS	-2.32	-1.45	17.41
2026-02-06	APLS	-2.32	-1.45	17.41
2026-02-09	APLS	-2.32	-2.57	17.50
2026-02-10	APLS	-2.27	-2.57	17.50
2026-02-11	APLS	-2.27	-2.57	20.53
2026-02-12	APLS	-2.27	-2.57	20.53
2026-02-13	APLS	-2.27	-2.57	20.53
2026-02-17	APLS	-2.27	2.18	20.53
2026-02-18	APLS	-2.27	2.18	20.53
2026-02-19	APLS	-2.27	2.18	20.53
2026-02-20	APLS	-2.25	2.18	20.55
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

20 items 1 of 1

Last Quarter Act. EPS

0.69

Avg. EPS Est. Current Quarter

-0.38

Avg. EPS Est. Next Quarter

-0.47

Insider Transactions

-2.25

Institutional Transactions

2.18

Beta

0.24

Average Sales Estimate Current Quarter

200

Average Sales Estimate Next Quarter

193

Fair Value

20.43

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

76.5

Max Drawdown 5-Year %

-82.5

Target Price

33.95

P/E

75.04

Forward P/E

PEG

P/S

2.77

P/B

7.03

P/Free Cash Flow

35.85

EPS

0.3

Average EPS Est. Cur. Y

0.28

EPS Next Y. (Est.)

-1.3

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

4.43

Relative Volume

0.54

Return on Equity vs Sector %

-17.8

Return on Equity vs Industry %

-0.3

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Apellis Pharmaceuticals, Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 705

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops EMPAVELI to treat C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, hematopoietic stem cell transplantation-associated thrombotic microangiopathy, focal segmental glomerulosclerosis, and delayed graft function; and APL-3007, a small interfering RNA, or siRNA for the treatment of GA. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.

stock quote shares APLS – Apellis Pharmaceuticals, Inc. Stock Price stock today

news today APLS – Apellis Pharmaceuticals, Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch APLS – Apellis Pharmaceuticals, Inc. yahoo finance google finance

stock history APLS – Apellis Pharmaceuticals, Inc. invest stock market

stock prices APLS premarket after hours

ticker APLS fair value insiders trading

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Upside

Beta

Ticker: APLS

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Last Quarter Act. EPS

Average EPS Est. Cur. Y